This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DSM-Firmenich Inkomsten in het verleden
Verleden criteriumcontroles 1/6
DSM-Firmenich's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 20.5% annually. Revenues have been declining at an average rate of 0.8% per year. DSM-Firmenich's return on equity is 4.4%, and it has net margins of 5.4%.
Belangrijke informatie
-20.7%
Groei van de winst
-20.2%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 13.1% |
| Inkomstengroei | -0.8% |
| Rendement op eigen vermogen | 4.4% |
| Nettomarge | 5.4% |
| Volgende winstupdate | 02 Aug 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe DSM-Firmenich geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 22 | 8,390 | 454 | 1,772 | 295 |
| 30 Sep 22 | 9,582 | 837 | 895 | 162 |
| 30 Jun 22 | 9,802 | 1,082 | 1,789 | 323 |
| 31 Mar 22 | 9,503 | 1,081 | 1,789 | 323 |
| 31 Dec 21 | 7,269 | 820 | 1,649 | 274 |
| 30 Sep 21 | 7,955 | 660 | 2,517 | 560 |
| 30 Jun 21 | 7,558 | 493 | 1,622 | 398 |
| 31 Mar 21 | 7,572 | 423 | 1,622 | 398 |
| 31 Dec 20 | 8,106 | 448 | 1,622 | 398 |
| 30 Sep 20 | 7,960 | 510 | 1,639 | 295 |
| 30 Jun 20 | 8,034 | 557 | 1,639 | 295 |
| 31 Mar 20 | 9,011 | 722 | 1,795 | 349 |
| 31 Dec 19 | 7,998 | 675 | 1,639 | 295 |
| 30 Sep 19 | 8,272 | 820 | 1,839 | 348 |
| 30 Jun 19 | 8,502 | 794 | 1,839 | 348 |
| 31 Mar 19 | 9,124 | 934 | 1,839 | 348 |
| 31 Dec 18 | 9,267 | 1,069 | 1,839 | 348 |
| 30 Sep 18 | 9,235 | 984 | 1,753 | 334 |
| 30 Jun 18 | 9,106 | 2,082 | 1,753 | 334 |
| 31 Mar 18 | 8,908 | 1,942 | 1,753 | 334 |
| 31 Dec 17 | 8,632 | 1,761 | 1,753 | 334 |
| 30 Sep 17 | 8,471 | 1,676 | 1,694 | 309 |
| 30 Jun 17 | 8,333 | 738 | 1,694 | 309 |
| 31 Mar 17 | 8,166 | 711 | 1,694 | 309 |
| 31 Dec 16 | 7,920 | 645 | 1,694 | 309 |
| 30 Sep 16 | 7,831 | 588 | 1,605 | 332 |
| 30 Jun 16 | 7,778 | 274 | 1,605 | 332 |
| 31 Mar 16 | 7,749 | 214 | 1,605 | 332 |
| 31 Dec 15 | 7,722 | 174 | 1,605 | 332 |
| 30 Sep 15 | 7,607 | 66 | 1,382 | 304 |
| 30 Jun 15 | 7,456 | 114 | 1,382 | 304 |
| 31 Mar 15 | 7,245 | 115 | 1,382 | 304 |
| 31 Dec 14 | 7,051 | 123 | 1,382 | 304 |
| 30 Sep 14 | 7,415 | 112 | 1,430 | 340 |
| 30 Jun 14 | 7,834 | 138 | 1,430 | 340 |
| 31 Mar 14 | 8,362 | 182 | 1,430 | 340 |
| 31 Dec 13 | 8,858 | 252 | 1,430 | 340 |
| 30 Sep 13 | 8,409 | 363 | 1,396 | 372 |
| 30 Jun 13 | 8,500 | 335 | 1,396 | 372 |
| 31 Mar 13 | 8,486 | 257 | 1,396 | 372 |
| 31 Dec 12 | 8,588 | 280 | 1,396 | 372 |
| 30 Sep 12 | 9,089 | 453 | 1,356 | 378 |
| 30 Jun 12 | 9,107 | 543 | 1,356 | 378 |
Kwaliteitswinsten: DSM N has high quality earnings.
Groeiende winstmarge: DSM N's current net profit margins (5.4%) are lower than last year (11.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DSM N's earnings have declined by 20.7% per year over the past 5 years.
Versnelling van de groei: DSM N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: DSM N had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Chemicals industry average (-12.7%).
Rendement op eigen vermogen
Hoge ROE: DSM N's Return on Equity (4.4%) is considered low.